Body Mass Index-Related Trends in Adverse Events with Enfortumab Vedotin: Analysis of a Pharmacovigilance Database and Medical Records. (PubMed, Biol Pharm Bull) - Sep 7, 2026 - "A high BMI was associated with an increased risk of certain EV-related skin toxicities, potentially exacerbated by dosing based on actual versus IBW, whereas a low BMI may increase susceptibility to infections such as pyelonephritis. Individualizing risk assessment and dosing based on patient physique may improve the safety and efficacy of EV therapy."
Adverse events • Journal • Retrospective data • Dermatology • Infectious Disease • Nephrology • Oncology • Pruritus • Solid Tumor • Steven-Johnson Syndrome • Urothelial Cancer
|
|
Motoki Kei; Ryosuke Yamaga; Satoko Karaki; Shiori Sato; Toshimasa Ito; Yoshihiro Uesawa
|